Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glasdegib with Chemotherapy in Untreated AML
NCT03416179Phase 3Completed
- Sponsor
- Pfizer
- Start
- Apr 2018
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 22
01
Overview
A Phase 3 trial of glasdegib in acute myeloid leukemia (AML), sponsored by Pfizer. Started Apr 2018; status: completed.
02
Drugs
glasdegib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03416179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03416179.